About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Breast Cancer Clinical Trials in Dallas | 559 Studies

Clinical Trials Breast CancerDallas

Breast Cancer Clinical Trials in Dallas

Find 559 clinical trials for breast cancer near Dallas, Texas. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 361-380 of 559 trials

Approved for marketingExpanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerThe treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.NCT02792725·Monterey, California and 9 others Active not recruitingStudy of Oral MRT-2359 in Selected Cancer PatientsThis Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung…NCT05546268·Scottsdale, Arizona and 16 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

Active not recruitingTesting Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerThis randomized phase II trial studies how well olaparib with or without atezolizumab work in treating patients with non-HER2-positive breast cancer that has spread to nearby…NCT02849496·Phoenix, Arizona and 57 others

Active not recruiting9-ING-41 in Patients With Advanced CancersGSK-3β is a potentially important therapeutic target in human malignancies.NCT03678883·Phoenix, Arizona and 65 others

CompletedDocetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast CancerRATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing.NCT01547741·Anchorage, Alaska and 914 others

RecruitingS1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityThis trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body.NCT03418961·Anchorage, Alaska and 589 others

Active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare TumorsThis phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.NCT02834013·Birmingham, Alabama and 1006 others

Active not recruitingT-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialThis phase III trial compares the effect of usual treatment with trastuzumab emtansine (T-DM1) alone vs. T-DM1 in combination with tucatinib.NCT04457596·Birmingham, Alabama and 1175 others

CompletedA Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsThis is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy…NCT03849469·Encinitas, California and 27 others

TerminatedTamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast CancerRATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer.NCT00096369·Oklahoma City, Oklahoma and 3 others

CompletedLapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast CancerThis study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic…NCT00320385·Phoenix, Arizona and 144 others

TerminatedREVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesPatients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w)…NCT03435640·Scottsdale, Arizona and 13 others

TerminatedStudy of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast CancerThis is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with…NCT07408089·Los Angeles, California and 7 others

CompletedA Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole TherapyThe purpose of this study is to assess the safety and efficacy of oral abiraterone acetate plus oral prednisone and oral abiraterone acetate plus oral prednisone plus oral…NCT01381874·Muscle Shoals, Alabama and 80 others

CompletedStudy to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersThe purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers.NCT02178722·La Jolla, California and 23 others

RecruitingOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerIncyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers.NCT05735080·Orlando, Florida and 17 others

RecruitingBAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaThis study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination…NCT05768932·New Haven, Connecticut and 16 others

RecruitingA First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerThis is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.NCT06638307·Springdale, Arkansas and 46 others

CompletedA Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerThe main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage…NCT00887536·Bessemer, Alabama and 532 others

RecruitingFirst-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerThis is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary…NCT05216432·Tucson, Arizona and 36 others

PreviousPage 19 of 28Next

Other Conditions in Dallas

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma